A Phase 3 interventional study of Obinutuzumab and Venetoclax in Chronic Lymphocytic Leukemia (CLL), sponsored by Hoffmann-La Roche. Completed at 40 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell — 16 open to participants now, 28 under way, 6 of them phase 3. obinutuzumab · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 14th largest by enrollment, is one of 6 that started in 2020, is one of 13 in phase 3, and was the 31st registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →16 of the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
BeOne Medicines · Sites in United States, Argentina, Australia and 18 more countries
Ages 18+
PETHEMA Foundation · Sites in Spain
Ages 18+
AbbVie · Sites in United States, Australia, France and 6 more countries
Ages 18+
By country, each count listing its studies:
obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 13
First in 2009; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 72 across the 53 interventional studies. Of the 22 that completed or were terminated, 14 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 53 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 13th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2020, is one of 10 in phase 3, and was the 46th registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
12 of the studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT04895436AbbVieStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | 2026-11 |
| NCT05943496OHSU Knight Cancer InstituteTafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | 2027-01-01 |
| NCT04722172Memorial Sloan Kettering Cancer CenterA Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | 2027-02 |
Add all 12 to your calendar (.ics) → With an account.
Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of ≤6 and a normal creatinine clearance of ≥70 mL/min) with previously untreated CLL without DEL(17P) or TP53 mutation requiring treatment. Eligible participants will be randomly assigned in a 1:1 ratio to receive either VEN + G (Arm A) or FCR/BR (Arm B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hematology values within the following limits, unless cytopenia is caused by the underlying disease (i.e., no evidence of additional bone marrow (BM) dysfunction; e.g., myelodysplastic syndrome, hypoplastic BM):
Exclusion Criteria:
Received any of the following agents within 28 days prior to the first dose of study treatment:
Participants who have received the following agents:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 12 cycles of treatment (each cycle is 28 days). Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
Drug: Obinutuzumab · Drug: Venetoclax
Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.
Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Rituximab · Drug: Bendamustine
Obinutuzumab 1000 milligrams (mg) will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
Also known as: Gazyva, RO5072759, GA101
Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.
Also known as: Venclexta, RO5537382, GDC-0199
Fludarabine will be administered in a dosage of 25 milligram per meter squared (mg/m\^2), IV, on days 1, 2, and 3 of Cycles 1-6.
Cyclophosphamide will be administered in a dosage of 250 mg/m\^2, IV, on Days 1, 2, and 3 Cycles 1-6.
Rituximab will be administered at a dose of 375 mg/m\^2, IV, on Cycle 1, Day 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.
Also known as: MabThera, Rituxan
Bendamustine will be administered at a dose of 90 mg/m\^2, IV, on 2 consecutive days of Cycles 1-6.
Also known as: Treanda, Levact, Ribomustin
Minimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS)
MRD response rate was determined as the percentage of participants with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. Percentages have been rounded off to the nearest decimal point.
Time frame: At Month 15
Progression-free Survival (PFS)
PFS was defined as the time from randomization to the first occurrence of disease progression (PD), or death from any cause. PD was assessed by the investigators using the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. PD was defined as any one of the following: Appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 centimeters \[cm\]); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/litres (L) B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; post treatment: progression of any cytopenia, documented by a decrease of hemoglobin (Hb) ≥ 2 grams per deciliter (g/dL) or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. Kaplan-Meier (K-M) method was used to determine PFS.
Time frame: Up to approximately 56.4 months
MRD Response Rate in PB of FCR/BR Compared With VEN+G at the End of Treatment Response Visit
MRD response rate was determined as the percentage of participants with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. Percentages have been rounded off to the nearest decimal point.
Time frame: VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)
MRD Response Rate in Bone Marrow (BM) of FCR/BR Compared With VEN+G at the End of Treatment Response Visit
MRD response rate=percentage of participants with MRD-negativity measured in BM using NGS (cutoff of \<10\^-4). MRD negativity=\<1 CLL cell in 10,000 leukocytes. MRD in BM was assessed for participants with complete response (CR)/CR with incomplete blood count recovery (CRi) \& partial response (PR). CR=PB lymphocytes \<4x10\^9 /L; Absence of significant lymphadenopathy (nodes \<1.5 cm in longest diameter); no hepatomegaly/splenomegaly; absence of disease/constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi=fulfilling CR criteria but with persistent anemia/thrombocytopenia/neutropenia. PR= ≥50% decrease in PB lymphocyte count from pre-treatment value; ≥50% reduction in lymphadenopathy (sum of longest diameter of up to 6 largest lymph nodes by physical exam \& 50% reduction in the sum of product of the diameter of up to 6 largest lymph nodes); ≥50% reduction of liver/spleen enlargement/normalization in size, if enlarged at baseline.
Time frame: VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)
Objective Response Rate (ORR)
ORR was defined as the percentage of participants with overall response (OR) of CR, CRi, and PR as determined by the investigator according to the iwCLL guidelines. CR was defined as PB lymphocytes \<4x10\^9 /L; absence of significant lymphadenopathy (nodes \<1.5 cm in longest diameter \[LD\]); no hepatomegaly/splenomegaly; absence of disease/constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as fulfilling CR criteria but with persistent anemia/thrombocytopenia/neutropenia. PR was defined as ≥50% decrease in PB lymphocyte count from pre-treatment value; ≥50% reduction in lymphadenopathy sum of longest diameter of up to 6 largest lymph nodes by physical exam and 50% reduction in the sum of product of the diameter of up to 6 largest lymph nodes); ≥50% reduction of liver/spleen enlargement/normalization in size, if enlarged at baseline.
Time frame: At Month 15
CR Rate
CR rate was defined as the percentage of participants with CR or CRi. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes (evaluated by blood and differential count) below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.
Time frame: At Month 15
MRD Response Rate in PB of Participants With a CR/CRi at the End of Treatment Visit
MRD response rate was determined as the percentage of participants (with a CR/CRi) with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.
Time frame: At Month 15
MRD Response Rate in BM of Participants With a CR/CRi at the End of Treatment Visit
MRD response rate was determined as the percentage of participants (with CR/CRi) with MRD-negativity measured in the BM using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria with CR but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.
Time frame: VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)
Duration of Objective Response (DOR)
DOR=time from first occurrence of a documented objective response (CR, CRi \& PR) to the time of PD as determined by the investigator, or death from any cause, whichever occurred first. CR, CRi, PR, \& PD were defined per the iwCLL guidelines. PD = any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. CR, CRi \& PR were defined as outlined in the description for ORR outcome measure. K-M method was used to determine DOR.
Time frame: Up to approximately 56.4 months
Best Overall Response (BOR)
BOR=percentage of participants with CR/CRi/PR/stable disease (SD)/PD per the investigator. Participants with best response as CR/CRi/PR were considered responders while those reaching SD/PD were non-responders. SD=participants who have not achieved a CR or a PR, or who have not exhibited PD. PD=any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. CR, CRi and PR were defined as outlined in the description for ORR, OM number 5.
Time frame: At Month 15
Event-free Survival (EFS)
EFS was defined as the time between the date of randomization and the date of PD/relapse, death, or the start of a new anti-leukemic therapy. PD was defined as any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. K-M method was used to determine EFS.
Time frame: Up to approximately 56.4 months
Overall Survival (OS)
OS was defined as the time between the date of randomization and the date of death due to any cause. K-M method was used to determine OS.
Time frame: Up to approximately 56.4 months
VEN + G: Tumor Lysis Syndrome (TLS) Risk Reduction Rate
TLS risk reduction rate in the VEN + G arm was defined as the reduction in the percentage of participants who were TLS high-risk after 3 doses of obinutuzumab compared to the percentage of participants who were TLS high-risk at baseline. Risk for developing TLS were categorised into: Low - All measurable lymph nodes with the LD \< 5 cm and \< 25x10\^9/L absolute lymphocyte count (ALC); Medium - Any measurable lymph node with the LD ≥5 cm but \<10 cm OR ≥25x10\^9/L ALC; High - Any measurable lymph node with the LD ≥10 cm or the presence of both ≥25x10\^9/L ALC and any measurable lymph node with the LD ≥5 cm but \<10 cm. Percentages have been rounded off to the nearest decimal point.
Time frame: Baseline up to Cycle 1 Day 22 (1 cycle=28 days)
VEN + G: Reduction in Mandatory Hospitalizations During Venetoclax Ramp-up
Reduction in mandatory hospitalizations during venetoclax ramp-up in the VEN + G arm participants was defined as the actual number of protocol-mandated hospitalizations for TLS monitoring during venetoclax ramp-up period after 3 doses of obinutuzumab compared to the number of protocol-mandated hospitalizations for TLS monitoring during venetoclax ramp-up expected at baseline. Ramp-up period for venetoclax was defined as period from Cycle 1, Days 22-28, and Cycle 2, Day 1-Day 7 where the 20 mg and 50 mg daily doses of venetoclax, were administered for participants at TLS-high risk requiring mandated hospitalizations (the hospitalizations at 100, 200 and 400 was only needed if the participant had a TLS event at one of the lower doses). Total number of hospitalizations in high-risk TLS participants at baseline (expected to be N=2 hospitalization) was compared with the number of protocol mandated hospitalizations during the first 2 doses of the ramp-up.
Time frame: Cycle 1 Days 22-28 up to Cycle 2 Days 1-7 (1 cycle=28 days)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE was any AE that meets any of the following criteria: is fatal; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug; is a significant medical event in the investigator's judgment.
Time frame: Up to approximately 56.4 months
Number of Participants With Premature Withdrawals Due to AEs
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Participants who withdrew from the study due to AEs are being reported here.
Time frame: Up to approximately 56.4 months
Change From Baseline in Physical Functioning Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQC-30)
The EORTC QLQ-C30 consists of 30 questions incorporated into 5 functional scales (physical, role, cognitive, emotional and social scales), 3 symptom scales (fatigue, pain, nausea, and vomiting scales), a global health status/global quality-of-life (GHS/QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The functioning items were scored on a 4-point scale (1=Not at All to 4=Very Much). Raw average scale scores were linearly transformed to range from 0-100. Higher scores=higher response levels (i.e. higher functioning). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. Time frame continued: Day 28 After Completion/Early Termination (ET) of Combination Therapy (VEN+G)/Day 28 After Treatment Completion (TC)/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.
Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, 3 & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; Follow-up (FU) at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
Change From Baseline in Role Functioning Assessed Using EORTC QLQC-30
The EORTC QLQ-C30 consists of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), a GHS/QoL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The functioning items were scored on a 4-point scale (1=Not at All to 4=Very Much). Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e. higher functioning). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at a given timepoint. Time frame continued: Day 28 After Completion/ ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.
Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, 3 & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
Change From Baseline in GHS/QoL Assessed Using EORTC QLQC-30
The EORTC QLQ-C30 consists of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), a GHS/QoL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The 2 GHS/QoL items were scored on a 7-point scale (1= Very poor to 7=Excellent). Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e. better QoL). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at a given timepoint. Time frame continued (TFC): Day 28 After Completion/ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approximately (approx) 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.
Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, 3 & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
Change From Baseline in Mean Core Symptom Severity Score as Measured by the M.D. Anderson Symptom Inventory (MDASI-CLL)
MDASI-CLL=25 items over 3 scales assessing core cancer \& CLL-related symptom severity \&symptom interference that a participant may have experienced in past 24 hours. Participants rated severity of 13 symptoms called mean core symptom severity (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting \& numbness/tingling) to assess mean core symptom severity score. Each symptom is scored from 0 (not present)-10 (as bad as you can imagine). Total score across all questions(0-130) was divided by number of questions. Mean score, ranged from 0-10. Lower scores=lower symptom severity. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. TFC: Day 28 After Completion/ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approx 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approx11 months.
Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
Change From Baseline in Mean Module Symptom Severity Score as Measured by MDASI-CLL
MDASI-CLL=25 items over 3 scales that assess core cancer \& CLL-related symptom severity, as well as symptom interference a participant may have experienced in past 24 hours. Participants were asked to rate the severity of 6 disease-specific symptoms called mean module symptom severity (night sweats, fever \& chills, lymph node swelling, diarrhea, easy bruising/bleeding \& constipation). Each symptom is scored on scale from 0-10, where 0=not present \& 10=as bad as you can imagine. The total score across all questions (0 to 60) was divided by the number of questions. The mean score, therefore, ranged from 0-10. Higher scores indicated more symptom severity. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. Time frame continued: Day 28 After Completion/ET of VEN+G/Day 28 After TC/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.
Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
Change From Baseline in Mean Interference Score as Measured by MDASI-CLL
MDASI-CLL consists of 25 items over 3 scales that assess core cancer \& CLL-related symptom severity, and symptom interference that a participant may have experienced in past 24 hours. Participants rated 6 mean interference on life questions (general activity, walking, work, mood, relations with other people \& enjoyment of life) to derive the Mean Interference Score. These were scored on a scale from 0 (symptom did not interfere)-10 (symptom interfered completely). Total score across all questions (0 to 60) was divided by number of questions. Mean score, therefore, ranged from 0-10. Higher scores=higher symptom interference. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed=participants with data available for analysis at a given timepoint. Time frame continued: Day 28 After Completion/ ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approx 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approx 11 months.
Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
A total of 166 participants with previously untreated chronic lymphocytic leukemia (CLL) without del (17p) or tumor protein p53 (TP53) mutation took part in the study at 38 investigative sites in France, Italy, Australia, Spain, and the United States from 28 May 2020 to 19 March 2025. The study is considered "Completed" because all the pre-planned study activities and analyses have been performed.
| Milestone | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Started | 80 | 86 |
| Safety population | 77 | 85 |
| Completed | 0 | 0 |
| Not completed | 80 | 86 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 3 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Reason not specified | 2 | 2 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Study ended by sponsor | 69 | 72 |
| Withdrew: Withdrawal by subject | 2 | 6 |
MRD response rate was determined as the percentage of participants with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. Percentages have been rounded off to the nearest decimal point.
| percentage of participants | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Minimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS) | 81.3 (70.97 to 89.11) | 54.7 (43.55 to 65.42) |
PFS was defined as the time from randomization to the first occurrence of disease progression (PD), or death from any cause. PD was assessed by the investigators using the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. PD was defined as any one of the following: Appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 centimeters \[cm\]); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/litres (L) B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; post treatment: progression of any cytopenia, documented by a decrease of hemoglobin (Hb) ≥ 2 grams per deciliter (g/dL) or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. Kaplan-Meier (K-M) method was used to determine PFS.
| months | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Progression-free Survival (PFS) | NA (NA to NA) | 53.3 (NA to NA) |
MRD response rate was determined as the percentage of participants with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. Percentages have been rounded off to the nearest decimal point.
| percentage of participants | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| MRD Response Rate in PB of FCR/BR Compared With VEN+G at the End of Treatment Response Visit | 81.3 (70.97 to 89.11) | 60.5 (49.34 to 70.85) |
MRD response rate=percentage of participants with MRD-negativity measured in BM using NGS (cutoff of \<10\^-4). MRD negativity=\<1 CLL cell in 10,000 leukocytes. MRD in BM was assessed for participants with complete response (CR)/CR with incomplete blood count recovery (CRi) \& partial response (PR). CR=PB lymphocytes \<4x10\^9 /L; Absence of significant lymphadenopathy (nodes \<1.5 cm in longest diameter); no hepatomegaly/splenomegaly; absence of disease/constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi=fulfilling CR criteria but with persistent anemia/thrombocytopenia/neutropenia. PR= ≥50% decrease in PB lymphocyte count from pre-treatment value; ≥50% reduction in lymphadenopathy (sum of longest diameter of up to 6 largest lymph nodes by physical exam \& 50% reduction in the sum of product of the diameter of up to 6 largest lymph nodes); ≥50% reduction of liver/spleen enlargement/normalization in size, if enlarged at baseline.
| percentage of participants | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| MRD Response Rate in Bone Marrow (BM) of FCR/BR Compared With VEN+G at the End of Treatment Response Visit | 70.0 (58.72 to 79.74) | 38.4 (28.08 to 49.49) |
ORR was defined as the percentage of participants with overall response (OR) of CR, CRi, and PR as determined by the investigator according to the iwCLL guidelines. CR was defined as PB lymphocytes \<4x10\^9 /L; absence of significant lymphadenopathy (nodes \<1.5 cm in longest diameter \[LD\]); no hepatomegaly/splenomegaly; absence of disease/constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as fulfilling CR criteria but with persistent anemia/thrombocytopenia/neutropenia. PR was defined as ≥50% decrease in PB lymphocyte count from pre-treatment value; ≥50% reduction in lymphadenopathy sum of longest diameter of up to 6 largest lymph nodes by physical exam and 50% reduction in the sum of product of the diameter of up to 6 largest lymph nodes); ≥50% reduction of liver/spleen enlargement/normalization in size, if enlarged at baseline.
| percentage of participants | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Objective Response Rate (ORR) | 88.8 (79.72 to 94.72) | 79.1 (68.95 to 87.10) |
CR rate was defined as the percentage of participants with CR or CRi. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes (evaluated by blood and differential count) below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.
| percentage of participants | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| CR Rate | 50.0 (38.60 to 61.40) | 32.6 (22.84 to 43.52) |
MRD response rate was determined as the percentage of participants (with a CR/CRi) with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.
| percentage of participants | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| MRD Response Rate in PB of Participants With a CR/CRi at the End of Treatment Visit | 97.5 (86.84 to 99.94) | 78.6 (59.05 to 91.70) |
MRD response rate was determined as the percentage of participants (with CR/CRi) with MRD-negativity measured in the BM using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria with CR but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.
| percentage of participants | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| MRD Response Rate in BM of Participants With a CR/CRi at the End of Treatment Visit | 87.5 (73.20 to 95.81) | 60.7 (40.58 to 78.50) |
DOR=time from first occurrence of a documented objective response (CR, CRi \& PR) to the time of PD as determined by the investigator, or death from any cause, whichever occurred first. CR, CRi, PR, \& PD were defined per the iwCLL guidelines. PD = any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. CR, CRi \& PR were defined as outlined in the description for ORR outcome measure. K-M method was used to determine DOR.
| months | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Duration of Objective Response (DOR) | NA (NA to NA) | 50.3 (50.3 to NA) |
BOR=percentage of participants with CR/CRi/PR/stable disease (SD)/PD per the investigator. Participants with best response as CR/CRi/PR were considered responders while those reaching SD/PD were non-responders. SD=participants who have not achieved a CR or a PR, or who have not exhibited PD. PD=any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. CR, CRi and PR were defined as outlined in the description for ORR, OM number 5.
| percentage of participants | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Best Overall Response (BOR) | 93.8 (86.01 to 97.94) | 90.7 (82.49 to 95.90) |
EFS was defined as the time between the date of randomization and the date of PD/relapse, death, or the start of a new anti-leukemic therapy. PD was defined as any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. K-M method was used to determine EFS.
| months | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Event-free Survival (EFS) | NA (NA to NA) | 53.3 (53.3 to NA) |
OS was defined as the time between the date of randomization and the date of death due to any cause. K-M method was used to determine OS.
| months | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
TLS risk reduction rate in the VEN + G arm was defined as the reduction in the percentage of participants who were TLS high-risk after 3 doses of obinutuzumab compared to the percentage of participants who were TLS high-risk at baseline. Risk for developing TLS were categorised into: Low - All measurable lymph nodes with the LD \< 5 cm and \< 25x10\^9/L absolute lymphocyte count (ALC); Medium - Any measurable lymph node with the LD ≥5 cm but \<10 cm OR ≥25x10\^9/L ALC; High - Any measurable lymph node with the LD ≥10 cm or the presence of both ≥25x10\^9/L ALC and any measurable lymph node with the LD ≥5 cm but \<10 cm. Percentages have been rounded off to the nearest decimal point.
| percentage of participants | Arm A: VEN+G |
|---|---|
| High-risk at Baseline | 23.8 |
| High-risk at Cycle 1 Day 22 | 0 |
Reduction in mandatory hospitalizations during venetoclax ramp-up in the VEN + G arm participants was defined as the actual number of protocol-mandated hospitalizations for TLS monitoring during venetoclax ramp-up period after 3 doses of obinutuzumab compared to the number of protocol-mandated hospitalizations for TLS monitoring during venetoclax ramp-up expected at baseline. Ramp-up period for venetoclax was defined as period from Cycle 1, Days 22-28, and Cycle 2, Day 1-Day 7 where the 20 mg and 50 mg daily doses of venetoclax, were administered for participants at TLS-high risk requiring mandated hospitalizations (the hospitalizations at 100, 200 and 400 was only needed if the participant had a TLS event at one of the lower doses). Total number of hospitalizations in high-risk TLS participants at baseline (expected to be N=2 hospitalization) was compared with the number of protocol mandated hospitalizations during the first 2 doses of the ramp-up.
| number of hospitalizations | Arm A: VEN+G |
|---|---|
| VEN + G: Reduction in Mandatory Hospitalizations During Venetoclax Ramp-up | 2 |
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE was any AE that meets any of the following criteria: is fatal; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug; is a significant medical event in the investigator's judgment.
| Participants | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| AEs | 76 | 83 |
| SAEs | 46 | 42 |
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Participants who withdrew from the study due to AEs are being reported here.
| Participants | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Number of Participants With Premature Withdrawals Due to AEs | 1 | 5 |
The EORTC QLQ-C30 consists of 30 questions incorporated into 5 functional scales (physical, role, cognitive, emotional and social scales), 3 symptom scales (fatigue, pain, nausea, and vomiting scales), a global health status/global quality-of-life (GHS/QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The functioning items were scored on a 4-point scale (1=Not at All to 4=Very Much). Raw average scale scores were linearly transformed to range from 0-100. Higher scores=higher response levels (i.e. higher functioning). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. Time frame continued: Day 28 After Completion/Early Termination (ET) of Combination Therapy (VEN+G)/Day 28 After Treatment Completion (TC)/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.
| score on a scale | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Baseline | 88.77 ± 16.09 | 88.33 ± 14.08 |
| Change at Cycle 1 Day 22 | -6.67 ± NA | — |
| Change at Cycle 2 Day 1 | -0.92 ± 9.05 | 0.30 ± 9.85 |
| Change at Cycle 2 Day 2 | — | 8.89 ± 13.88 |
| Change at Cycle 2 Day 3 | — | -13.33 ± NA |
| Change at Cycle 2 Day 22 | 13.33 ± NA | — |
| Change at Cycle 3 Day 1 | -1.03 ± 11.23 | -1.47 ± 15.72 |
| Change at Cycle 3 Day 2 | — | 0.00 ± NA |
| Change at Cycle 4 Day 1 | 0.00 ± 13.86 | 0.51 ± 13.32 |
| Change at Cycle 4 Day 2 | — | 6.67 ± NA |
| Change at Cycle 5 Day 1 | 0.25 ± 14.32 | -0.83 ± 13.16 |
| Change at Cycle 5 Day 2 | — | -6.67 ± NA |
| Change at Cycle 6 Day 1 | 1.03 ± 15.07 | -0.97 ± 12.97 |
| Change at Day 28 After Completion/Early Termination of Combination Visit | 6.67 ± 32.20 | — |
| Change at Day 28 After Treatment Completion Or Early Termination | -10.00 ± 14.14 | -3.27 ± 17.59 |
| Change at Cycle 7 Day 1 | -0.64 ± 18.31 | — |
| Change at Cycle 8 Day 1 | 0.95 ± 13.94 | — |
| Change at Cycle 9 Day 1 | 0.28 ± 14.87 | — |
| Change at Cycle 10 Day 1 | 0.99 ± 14.64 | — |
| Change at Cycle 11 Day 1 | 2.32 ± 13.57 | — |
| Change at Cycle 12 Day 1 | 1.04 ± 11.19 | — |
| Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy | -2.41 ± 18.60 | — |
| Change at FU Month 3 | -14.44 ± 38.97 | 0.00 ± 14.61 |
| Change at FU Month 6 | -1.27 ± 19.60 | 0.61 ± 16.32 |
| Change at FU Month 9 | 1.08 ± 18.09 | 0.65 ± 13.48 |
| Change at FU Month 12 | -1.67 ± 18.47 | 0.31 ± 14.03 |
| Change at FU Month 15 | 0.33 ± 16.47 | -1.05 ± 13.02 |
| Change at FU Month 18 | 1.05 ± 13.82 | 0.21 ± 13.91 |
| Change at FU Month 21 | -1.67 ± 17.10 | 1.43 ± 13.25 |
| Change at FU Month 24 | 0.83 ± 18.99 | 1.98 ± 13.81 |
| Change at FU Month 27 | — | -0.33 ± 11.13 |
| Change at FU Month 30 | -0.74 ± 5.21 | — |
| Change at FU Month 33 | — | -2.22 ± 10.89 |
| Change at FU Month 36 | 6.67 ± NA | — |
The EORTC QLQ-C30 consists of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), a GHS/QoL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The functioning items were scored on a 4-point scale (1=Not at All to 4=Very Much). Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e. higher functioning). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at a given timepoint. Time frame continued: Day 28 After Completion/ ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.
| score on a scale | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Baseline | 85.67 ± 20.28 | 83.06 ± 23.67 |
| Change at Cycle 1 Day 22 | -33.33 ± NA | — |
| Change at Cycle 2 Day 1 | -3.59 ± 18.05 | 3.79 ± 18.97 |
| Change at Cycle 2 Day 2 | — | 22.22 ± 25.46 |
| Change at Cycle 2 Day 3 | — | 0.00 ± NA |
| Change at Cycle 2 Day 22 | 16.67 ± NA | — |
| Change at Cycle 3 Day 1 | -1.28 ± 16.12 | 1.33 ± 28.74 |
| Change at Cycle 3 Day 2 | — | 0.00 ± NA |
| Change at Cycle 4 Day 1 | -0.98 ± 22.46 | 1.60 ± 26.66 |
| Change at Cycle 4 Day 2 | — | 0.00 ± NA |
| Change at Cycle 5 Day 1 | 0.31 ± 21.31 | 2.08 ± 20.81 |
| Change at Cycle 5 Day 2 | — | -16.67 ± NA |
| Change at Cycle 6 Day 1 | -1.28 ± 27.78 | 0.69 ± 26.40 |
| Change at Day 28 After Completion/Early Termination of Combination Visit | -8.33 ± 21.52 | — |
| Change at Day 28 After Treatment Completion Or Early Termination | -8.33 ± 11.79 | -1.02 ± 29.54 |
| Change at Cycle 7 Day 1 | -5.13 ± 27.72 | — |
| Change at Cycle 8 Day 1 | 1.70 ± 23.38 | — |
| Change at Cycle 9 Day 1 | -2.08 ± 24.70 | — |
| Change at Cycle 10 Day 1 | -2.13 ± 24.48 | — |
| Change at Cycle 11 Day 1 | 3.62 ± 23.28 | — |
| Change at Cycle 12 Day 1 | -0.74 ± 22.46 | — |
| Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy | -4.63 ± 29.17 | — |
| Change at FU Month 3 | -19.44 ± 42.71 | 2.90 ± 27.29 |
| Change at FU Month 6 | -1.98 ± 28.80 | 6.06 ± 30.23 |
| Change at FU Month 9 | 2.25 ± 27.54 | 2.44 ± 25.16 |
| Change at FU Month 12 | 1.25 ± 27.83 | -1.55 ± 28.13 |
| Change at FU Month 15 | 0.00 ± 26.95 | -3.51 ± 19.05 |
| Change at FU Month 18 | 3.07 ± 21.87 | -1.04 ± 26.07 |
| Change at FU Month 21 | -4.17 ± 26.10 | 6.55 ± 24.57 |
| Change at FU Month 24 | 2.08 ± 24.23 | 3.70 ± 26.69 |
| Change at FU Month 27 | — | 2.50 ± 23.12 |
| Change at FU Month 30 | -3.70 ± 20.03 | — |
| Change at FU Month 33 | — | 2.78 ± 19.48 |
| Change at FU Month 36 | 0.00 ± NA | — |
The EORTC QLQ-C30 consists of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), a GHS/QoL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The 2 GHS/QoL items were scored on a 7-point scale (1= Very poor to 7=Excellent). Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e. better QoL). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at a given timepoint. Time frame continued (TFC): Day 28 After Completion/ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approximately (approx) 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.
| score on a scale | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Baseline | 73.10 ± 19.48 | 72.64 ± 21.48 |
| Change at Cycle 1 Day 22 | -25.00 ± NA | — |
| Change at Cycle 2 Day 1 | 2.78 ± 18.91 | 1.85 ± 19.45 |
| Change at Cycle 2 Day 2 | — | 11.11 ± 34.69 |
| Change at Cycle 2 Day 3 | — | 8.33 ± NA |
| Change at Cycle 2 Day 22 | 33.33 ± NA | — |
| Change at Cycle 3 Day 1 | 3.21 ± 19.68 | -0.50 ± 26.91 |
| Change at Cycle 3 Day 2 | — | -25.00 ± NA |
| Change at Cycle 4 Day 1 | 1.47 ± 21.71 | 1.12 ± 23.22 |
| Change at Cycle 4 Day 2 | — | -25.00 ± NA |
| Change at Cycle 5 Day 1 | 2.67 ± 23.61 | 2.95 ± 21.71 |
| Change at Cycle 5 Day 2 | — | -25.00 ± NA |
| Change at Cycle 6 Day 1 | 0.00 ± 26.51 | -2.43 ± 22.08 |
| Change at Day 28 After Completion/Early Termination of Combination Visit | 4.17 ± 43.30 | — |
| Change at Day 28 After Treatment Completion or Early Termination | 0.00 ± 0.00 | -4.25 ± 22.38 |
| Change at Cycle 7 Day 1 | -2.40 ± 20.90 | — |
| Change at Cycle 8 Day 1 | 1.36 ± 20.22 | — |
| Change at Cycle 9 Day 1 | 0.87 ± 20.28 | — |
| Change at Cycle 10 Day 1 | 0.71 ± 22.84 | — |
| Change at Cycle 11 Day 1 | 3.99 ± 26.04 | — |
| Change at Cycle 12 Day 1 | 4.07 ± 19.91 | — |
| Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy | -1.85 ± 27.10 | — |
| Change at FU Month 3 | -33.33 ± 32.06 | 1.45 ± 23.79 |
| Change at FU Month 6 | 2.98 ± 22.68 | 2.65 ± 27.74 |
| Change at FU Month 9 | 4.50 ± 24.26 | -1.02 ± 21.10 |
| Change at FU Month 12 | -0.42 ± 24.89 | -0.39 ± 23.98 |
| Change at FU Month 15 | -0.62 ± 23.30 | -2.19 ± 21.98 |
| Change at FU Month 18 | 4.39 ± 20.11 | 3.39 ± 22.88 |
| Change at FU Month 21 | 0.52 ± 21.99 | 7.44 ± 21.79 |
| Change at FU Month 24 | 5.90 ± 22.45 | 3.70 ± 25.04 |
| Change at FU Month 27 | — | 3.33 ± 21.86 |
| Change at FU Month 30 | 2.78 ± 25.00 | — |
| Change at FU Month 33 | — | 6.94 ± 30.92 |
| Change at FU Month 36 | 16.67 ± NA | — |
MDASI-CLL=25 items over 3 scales assessing core cancer \& CLL-related symptom severity \&symptom interference that a participant may have experienced in past 24 hours. Participants rated severity of 13 symptoms called mean core symptom severity (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting \& numbness/tingling) to assess mean core symptom severity score. Each symptom is scored from 0 (not present)-10 (as bad as you can imagine). Total score across all questions(0-130) was divided by number of questions. Mean score, ranged from 0-10. Lower scores=lower symptom severity. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. TFC: Day 28 After Completion/ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approx 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approx11 months.
| score on a scale | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Baseline | 1.75 ± 1.53 | 1.66 ± 1.50 |
| Change at Cycle 1 Day 22 | 0.46 ± NA | — |
| Change at Cycle 2 Day 1 | -0.43 ± 1.32 | -0.20 ± 1.49 |
| Change at Cycle 2 Day 2 | — | 0.38 ± 0.98 |
| Change at Cycle 2 Day 22 | 0.08 ± NA | — |
| Change at Cycle 3 Day 1 | -0.33 ± 1.45 | -0.23 ± 1.37 |
| Change at Cycle 3 Day 2 | — | -0.23 ± NA |
| Change at Cycle 4 Day 1 | -0.27 ± 1.39 | -0.15 ± 1.51 |
| Change at Cycle 4 Day 2 | — | 0.54 ± NA |
| Change at Cycle 5 Day 1 | -0.32 ± 1.44 | -0.08 ± 1.25 |
| Change at Cycle 5 Day 2 | — | 2.46 ± NA |
| Change at Cycle 6 Day 1 | -0.41 ± 1.27 | -0.10 ± 1.58 |
| Change at Day 28 After Completion/Early Termination of Combination Therapy | 0.25 ± 2.53 | — |
| Change at Day 28 After Treatment Completion or Early Termination | 0.23 ± 0.76 | -0.33 ± 1.74 |
| Change at Cycle 7 Day 1 | -0.24 ± 1.63 | — |
| Change at Cycle 8 Day 1 | -0.55 ± 1.36 | — |
| Change at Cycle 9 Day 1 | -0.50 ± 1.39 | — |
| Change at Cycle 10 Day 1 | -0.42 ± 1.68 | — |
| Change at Cycle 11 Day 1 | -0.62 ± 1.45 | — |
| Change at Cycle 12 Day 1 | -0.39 ± 1.51 | — |
| Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy | -0.50 ± 1.55 | — |
| Change at FU Month 3 | -0.44 ± 2.73 | -0.37 ± 1.43 |
| Change at FU Month 6 | -0.43 ± 1.69 | -0.48 ± 1.68 |
| Change at FU Month 9 | -0.47 ± 1.61 | -0.23 ± 1.34 |
| Change at FU Month 12 | -0.43 ± 1.60 | -0.28 ± 1.32 |
| Change at FU Month 15 | -0.31 ± 1.52 | -0.18 ± 1.22 |
| Change at FU Month 18 | -0.30 ± 1.36 | -0.36 ± 1.46 |
| Change at FU Month 21 | -0.03 ± 1.48 | -0.34 ± 1.19 |
| Change at FU Month 24 | -0.29 ± 1.68 | -0.48 ± 1.20 |
| Change at FU Month 27 | — | -0.49 ± 1.45 |
| Change at FU Month 30 | -0.85 ± 1.94 | — |
| Change at FU Month 33 | — | -0.36 ± 1.54 |
| Change at FU Month 36 | 0.38 ± NA | — |
MDASI-CLL=25 items over 3 scales that assess core cancer \& CLL-related symptom severity, as well as symptom interference a participant may have experienced in past 24 hours. Participants were asked to rate the severity of 6 disease-specific symptoms called mean module symptom severity (night sweats, fever \& chills, lymph node swelling, diarrhea, easy bruising/bleeding \& constipation). Each symptom is scored on scale from 0-10, where 0=not present \& 10=as bad as you can imagine. The total score across all questions (0 to 60) was divided by the number of questions. The mean score, therefore, ranged from 0-10. Higher scores indicated more symptom severity. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. Time frame continued: Day 28 After Completion/ET of VEN+G/Day 28 After TC/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.
| score on a scale | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Baseline | 1.63 ± 1.53 | 1.43 ± 1.28 |
| Change at Cycle 1 Day 22 | -0.83 ± NA | — |
| Change at Cycle 2 Day 1 | -0.67 ± 1.33 | -0.63 ± 1.81 |
| Change at Cycle 2 Day 2 | — | -0.58 ± 1.30 |
| Change at Cycle 2 Day 22 | -1.50 ± NA | — |
| Change at Cycle 3 Day 1 | -0.82 ± 1.27 | -0.80 ± 1.21 |
| Change at Cycle 3 Day 2 | — | -1.00 ± NA |
| Change at Cycle 4 Day 1 | -0.74 ± 1.19 | -1.01 ± 1.20 |
| Change at Cycle 4 Day 2 | — | -0.33 ± NA |
| Change at Cycle 5 Day 1 | -0.84 ± 1.29 | -0.94 ± 1.08 |
| Change at Cycle 5 Day 2 | — | -0.17 ± NA |
| Change at Cycle 6 Day 1 | -0.93 ± 1.21 | -0.86 ± 1.17 |
| Change at Day 28 After Completion/Early Termination of Combination Therapy | -0.21 ± 0.75 | — |
| Change at Day 28 After Treatment Completion or Early Termination | -0.83 ± 1.18 | -0.90 ± 1.27 |
| Change at Cycle 7 Day 1 | -0.87 ± 1.42 | — |
| Change at Cycle 8 Day 1 | -0.98 ± 1.29 | — |
| Change at Cycle 9 Day 1 | -1.00 ± 1.36 | — |
| Change at Cycle 10 Day 1 | -1.02 ± 1.34 | — |
| Change at Cycle 11 Day 1 | -1.07 ± 1.32 | — |
| Change at Cycle 12 Day 1 | -1.10 ± 1.41 | — |
| Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy | -1.05 ± 1.45 | — |
| Change at FU Month 3 | -1.78 ± 1.85 | -0.76 ± 1.29 |
| Change at FU Month 6 | -1.20 ± 1.43 | -0.55 ± 1.35 |
| Change at FU Month 9 | -1.23 ± 1.50 | -0.97 ± 1.38 |
| Change at FU Month 12 | -1.05 ± 1.54 | -0.83 ± 1.15 |
| Change at FU Month 15 | -1.15 ± 1.38 | -0.58 ± 1.18 |
| Change at FU Month 18 | -1.03 ± 1.51 | -0.90 ± 1.34 |
| Change at FU Month 21 | -0.94 ± 1.50 | -0.93 ± 1.09 |
| Change at FU Month 24 | -0.93 ± 1.57 | -1.14 ± 1.30 |
| Change at FU Month 27 | — | -0.90 ± 1.20 |
| Change at FU Month 30 | -1.23 ± 1.82 | — |
| Change at FU Month 33 | — | -1.83 ± 1.33 |
| Change at FU Month 36 | 0.50 ± NA | — |
MDASI-CLL consists of 25 items over 3 scales that assess core cancer \& CLL-related symptom severity, and symptom interference that a participant may have experienced in past 24 hours. Participants rated 6 mean interference on life questions (general activity, walking, work, mood, relations with other people \& enjoyment of life) to derive the Mean Interference Score. These were scored on a scale from 0 (symptom did not interfere)-10 (symptom interfered completely). Total score across all questions (0 to 60) was divided by number of questions. Mean score, therefore, ranged from 0-10. Higher scores=higher symptom interference. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed=participants with data available for analysis at a given timepoint. Time frame continued: Day 28 After Completion/ ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approx 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approx 11 months.
| score on a scale | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Baseline | 2.11 ± 2.18 | 2.17 ± 2.39 |
| Change at Cycle 1 Day 22 | 1.33 ± NA | — |
| Change at Cycle 2 Day 1 | -0.23 ± 1.91 | -0.29 ± 2.30 |
| Change at Cycle 2 Day 2 | — | 0.17 ± 0.24 |
| Change at Cycle 2 Day 22 | -1.67 ± NA | — |
| Change at Cycle 3 Day 1 | -0.28 ± 2.22 | -0.51 ± 2.47 |
| Change at Cycle 3 Day 2 | — | 0.33 ± NA |
| Change at Cycle 4 Day 1 | -0.29 ± 2.41 | -0.30 ± 2.53 |
| Change at Cycle 4 Day 2 | — | 0.50 ± NA |
| Change at Cycle 5 Day 1 | -0.35 ± 2.38 | -0.43 ± 2.22 |
| Change at Cycle 5 Day 2 | — | 2.00 ± NA |
| Change at Cycle 6 Day 1 | -0.52 ± 2.17 | -0.11 ± 2.45 |
| Change at Day 28 After Completion/Early Termination of Combination Therapy | -0.62 ± 4.40 | — |
| Change at Day 28 After Treatment Completion or Early Termination | 0.33 ± 0.94 | -0.63 ± 2.45 |
| Change at Cycle 7 Day 1 | -0.01 ± 2.47 | — |
| Change at Cycle 8 Day 1 | -0.43 ± 2.37 | — |
| Change at Cycle 9 Day 1 | -0.13 ± 2.57 | — |
| Change at Cycle 10 Day 1 | -0.51 ± 2.49 | — |
| Change at Cycle 11 Day 1 | -0.54 ± 2.49 | — |
| Change at Cycle 12 Day 1 | -0.31 ± 2.22 | — |
| Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy | -0.33 ± 2.43 | — |
| Change at FU Month 3 | 0.47 ± 3.71 | -0.47 ± 2.50 |
| Change at FU Month 6 | -0.27 ± 2.78 | 0.19 ± 2.82 |
| Change at FU Month 9 | -0.60 ± 2.49 | -0.25 ± 2.13 |
| Change at FU Month 12 | -0.40 ± 2.24 | -0.35 ± 2.20 |
| Change at FU Month 15 | -0.34 ± 2.32 | -0.37 ± 2.02 |
| Change at FU Month 18 | -0.54 ± 2.11 | -0.44 ± 2.28 |
| Change at FU Month 21 | -0.21 ± 1.91 | -0.39 ± 2.05 |
| Change at FU Month 24 | -0.75 ± 2.63 | -0.80 ± 1.97 |
| Change at FU Month 27 | — | -0.66 ± 2.11 |
| Change at FU Month 30 | -1.08 ± 2.19 | — |
| Change at FU Month 33 | — | -1.14 ± 2.90 |
| Change at FU Month 36 | 2.00 ± NA | — |
Collected over Up to 56.4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: VEN+G | 3/80 (3.8%) | 46/77 (59.7%) | 76/77 (98.7%) |
| Arm B: FCR/BR | 3/86 (3.5%) | 42/85 (49.4%) | 81/85 (95.3%) |
| Event | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 9/77 | 6/85 |
| PyrexiaGeneral disorders | 6/77 | 9/85 |
| COVID-19Infections and infestations | 8/77 | 6/85 |
| COVID-19 pneumoniaInfections and infestations | 7/77 | 5/85 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/77 | 7/85 |
| SepsisInfections and infestations | 1/77 | 4/85 |
| PneumoniaInfections and infestations | 3/77 | 1/85 |
| NeutropeniaBlood and lymphatic system disorders | 2/77 | 3/85 |
| Atrial fibrillationCardiac disorders | 0/77 | 2/85 |
| Neutrophil count decreasedInvestigations | 1/77 | 2/85 |
| Event | Arm A: VEN+G | Arm B: FCR/BR |
|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 50/77 | 35/85 |
| NeutropeniaBlood and lymphatic system disorders | 43/77 | 37/85 |
| COVID-19Infections and infestations | 32/77 | 27/85 |
| ThrombocytopeniaBlood and lymphatic system disorders | 30/77 | 18/85 |
| NauseaGastrointestinal disorders | 16/77 | 33/85 |
| DiarrhoeaGastrointestinal disorders | 26/77 | 9/85 |
| RashSkin and subcutaneous tissue disorders | 5/77 | 23/85 |
| VomitingGastrointestinal disorders | 4/77 | 20/85 |
| ConstipationGastrointestinal disorders | 7/77 | 19/85 |
| FatigueGeneral disorders | 9/77 | 14/85 |
Full Analysis Set (FAS) included all randomized participants, analyzed according to the treatment to which they were randomized.
| Age, Continuous(years) | Arm A: VEN+G | Arm B: FCR/BR | Total |
|---|---|---|---|
| Mean | 61.5 ± 9.1 | 61.0 ± 8.6 | 61.2 ± 8.8 |
| Sex: Female, Male(Participants) | Arm A: VEN+G | Arm B: FCR/BR | Total |
|---|---|---|---|
| Female | 25 | 29 | 54 |
| Male | 55 | 57 | 112 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: VEN+G | Arm B: FCR/BR | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 10 |
| Not Hispanic or Latino | 50 | 62 | 112 |
| Unknown or Not Reported | 25 | 19 | 44 |
| Race (NIH/OMB)(Participants) | Arm A: VEN+G | Arm B: FCR/BR | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 58 | 73 | 131 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 20 | 11 | 31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing).
Ran from May 2020 to primary completion in Mar 2024, 45 months.
Results were first posted in Apr 2025, 1 year after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 45 months is below that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Obinutuzumab · Venetoclax
Leukemia, Lymphocytic, Chronic, B-Cell →